NL300684I2 - - Google Patents
Download PDFInfo
- Publication number
- NL300684I2 NL300684I2 NL300684C NL300684C NL300684I2 NL 300684 I2 NL300684 I2 NL 300684I2 NL 300684 C NL300684 C NL 300684C NL 300684 C NL300684 C NL 300684C NL 300684 I2 NL300684 I2 NL 300684I2
- Authority
- NL
- Netherlands
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39871102P | 2002-07-25 | 2002-07-25 | |
| PCT/EP2003/050322 WO2004011436A1 (en) | 2002-07-25 | 2003-07-18 | Quinoline derivatives and their use as mycobacterial inhibitors |
| EP03771115A EP1527050B1 (en) | 2002-07-25 | 2003-07-18 | Quinoline derivatives and their use as mycobacterial inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL300684I2 true NL300684I2 (nl) | 2016-10-11 |
Family
ID=31188461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL300684C NL300684I2 (nl) | 2002-07-25 | 2014-08-14 |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US7498343B2 (nl) |
| EP (2) | EP1527050B1 (nl) |
| JP (1) | JP4484703B2 (nl) |
| KR (1) | KR100733577B1 (nl) |
| CN (2) | CN101070304B (nl) |
| AP (1) | AP2421A (nl) |
| AR (1) | AR040673A1 (nl) |
| AT (1) | ATE463482T1 (nl) |
| AU (1) | AU2003262529B2 (nl) |
| BE (1) | BE2014C051I2 (nl) |
| BR (1) | BRPI0312927B8 (nl) |
| CA (1) | CA2493225C (nl) |
| CY (3) | CY1111882T1 (nl) |
| DE (1) | DE60332023D1 (nl) |
| DK (2) | DK2301544T3 (nl) |
| EA (1) | EA008937B1 (nl) |
| ES (2) | ES2343458T3 (nl) |
| FR (1) | FR14C0060I2 (nl) |
| HK (2) | HK1083496A1 (nl) |
| HR (2) | HRP20050045B1 (nl) |
| HU (1) | HUS1400047I1 (nl) |
| IL (2) | IL166457A (nl) |
| IS (1) | IS2914B (nl) |
| LU (1) | LU92520I2 (nl) |
| ME (1) | ME00131B (nl) |
| MX (1) | MXPA05001052A (nl) |
| MY (1) | MY143564A (nl) |
| NL (1) | NL300684I2 (nl) |
| NO (2) | NO329935B1 (nl) |
| NZ (1) | NZ538391A (nl) |
| PL (1) | PL222801B1 (nl) |
| PT (2) | PT1527050E (nl) |
| RS (1) | RS52431B (nl) |
| SI (2) | SI1527050T1 (nl) |
| TW (1) | TWI323730B (nl) |
| UA (1) | UA82198C2 (nl) |
| WO (1) | WO2004011436A1 (nl) |
| ZA (1) | ZA200500680B (nl) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2553269C (en) * | 2004-01-23 | 2012-07-10 | Janssen Pharmaceutica N.V. | Quinoline derivatives and use thereof as mycobacterial inhibitors |
| CN1910177B (zh) * | 2004-01-23 | 2010-05-05 | 詹森药业有限公司 | 取代的喹啉及其作为分枝杆菌抑制剂的用途 |
| NZ547614A (en) | 2004-01-29 | 2009-04-30 | Janssen Pharmaceutica Nv | Quinoline derivatives for use as mycobacterial inhibitors |
| CA2566544C (en) * | 2004-05-28 | 2012-04-17 | Janssen Pharmaceutica N.V. | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases |
| CA2579971C (en) * | 2004-09-28 | 2018-02-13 | Janssen Pharmaceutica N.V. | A bacterial atp synthase binding domain |
| EE05394B1 (et) * | 2004-12-24 | 2011-04-15 | Janssen Pharmaceutica N.V. | Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis |
| EA009779B1 (ru) * | 2004-12-24 | 2008-04-28 | Янссен Фармацевтика Н.В. | Лечение латентного туберкулёза |
| EA011770B1 (ru) * | 2005-05-25 | 2009-06-30 | Янссен Фармацевтика Н.В. | Способ получения (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола |
| CA2528849C (en) * | 2005-06-08 | 2014-01-14 | Janssen Pharmaceutica N.V. | Quinoline derivatives as antibacterial agents |
| TWI380819B (zh) * | 2005-06-08 | 2013-01-01 | Janssen Pharmaceutica Nv | 用作抗細菌劑之喹啉衍生物 |
| EA010601B1 (ru) * | 2005-06-09 | 2008-10-30 | Янссен Фармацевтика Н.В. | Производные хинолина в качестве антибактериальных агентов |
| KR101318181B1 (ko) * | 2005-06-09 | 2013-10-16 | 얀센 파마슈티카 엔.브이. | 항균제로서의 퀴놀린 유도체 |
| JP5349730B2 (ja) * | 2005-06-09 | 2013-11-20 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗バクテリア剤としてのキノリン誘導体 |
| JO3270B1 (ar) * | 2005-06-28 | 2018-09-16 | Janssen Pharmaceutica Nv | مشتقات كوينولين بصفة عوامل مضادة للبكتيريا |
| WO2007000434A1 (en) * | 2005-06-28 | 2007-01-04 | Janssen Pharmaceutica N.V. | Quinoline derivatives as antibacterial agents |
| JO2752B1 (en) * | 2005-06-28 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
| JO3077B1 (ar) * | 2005-07-28 | 2017-03-15 | Janssen Pharmaceutica Nv | مشتقات كوينولين مضادة للبكتيريا |
| JO2837B1 (en) * | 2005-08-03 | 2014-09-15 | جانسن فارمسيتكا ان في | Quinoline derivatives acting as antibacterial agents |
| JO2855B1 (en) * | 2005-08-03 | 2015-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
| JO2952B1 (en) | 2005-08-03 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
| US8686002B2 (en) | 2005-08-21 | 2014-04-01 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as binding partners for 5-HT5 receptors |
| DE102005044817A1 (de) | 2005-09-20 | 2007-03-22 | Sanofi-Aventis Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| UA97813C2 (uk) * | 2006-12-05 | 2012-03-26 | Янссен Фармацевтика Н.В. | Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу |
| JO3271B1 (ar) * | 2006-12-06 | 2018-09-16 | Janssen Pharmaceutica Nv | مشتقات الكوينولين المضادة للجراثيم |
| JO2683B1 (en) * | 2006-12-06 | 2013-03-03 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
| JO2725B1 (en) * | 2006-12-06 | 2013-09-15 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
| JO2970B1 (en) | 2006-12-06 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
| JO2684B1 (en) * | 2006-12-06 | 2013-03-03 | جانسين فارماسوتيكا ان في | Quinoline antibacterial derivatives |
| JO2685B1 (en) * | 2006-12-06 | 2013-03-03 | جانسين فارماسوتيكا ان في | Quinoline antibacterial derivatives |
| RU2404971C2 (ru) * | 2008-12-02 | 2010-11-27 | ЗАО "Фарм-Синтез" | Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе |
| CN102249935B (zh) * | 2010-05-17 | 2015-05-20 | 中国人民解放军军事医学科学院毒物药物研究所 | 芳香2-丁醇类化合物及其医药用途 |
| RU2486175C2 (ru) * | 2011-09-12 | 2013-06-27 | Закрытое Акционерное Общество "Фарм-Синтез" | Производные хинолина, в частности 5,6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ получения и применение соединений |
| CN104254527B (zh) | 2012-04-27 | 2017-05-31 | 詹森药业有限公司 | 抗菌的喹啉衍生物 |
| EP2841426B1 (en) | 2012-04-27 | 2016-09-28 | Janssen Pharmaceutica N.V. | Antibacterial quinoline derivatives |
| WO2014014845A1 (en) | 2012-07-18 | 2014-01-23 | Vertex Pharmaceuticals Incorporated | Combination therapy comprising|1 -ethyl-3-[5-[2-{1 -hydroxy-1 -methyl-ethyl}pyrimidin-5-yl]-7-(tetra hydrofuran-2-|yl}-1 h-benzimidazol-2-yl]urea and derivatives thereof to treat mycobacterium|diseases |
| SG11201504873RA (en) | 2012-12-21 | 2015-07-30 | Janssen Sciences Ireland Uc | Antibacterial compounds |
| RU2530493C1 (ru) * | 2013-04-22 | 2014-10-10 | Закрытое Акционерное Общество "Фарм-Синтез" | Производные хинолина, в частности 6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ их получения и применение соединений для лечения инфекционных заболеваний микобактериальной природы, в частности туберкулеза |
| CN105017147B (zh) * | 2014-04-30 | 2019-02-01 | 中国医学科学院药物研究所 | 一种回收和利用Bedaquiline立体化学异构体的方法 |
| CN105085395B (zh) * | 2014-05-07 | 2017-09-26 | 国药集团国瑞药业有限公司 | 贝达喹啉的制备方法 |
| CN105085396B (zh) * | 2014-05-07 | 2017-08-08 | 国药集团国瑞药业有限公司 | 用于制备贝达喹啉的中间体及其制备方法和应用 |
| CN105198808B (zh) * | 2014-05-27 | 2017-08-25 | 北京万生药业有限责任公司 | 一种高效生产贝达喹啉的方法 |
| CN105175329B (zh) * | 2014-06-10 | 2017-09-19 | 重庆圣华曦药业股份有限公司 | 一种贝达喹啉消旋体的合成路线及方法 |
| JP6362235B2 (ja) * | 2014-07-14 | 2018-07-25 | ツーセン ファーマシューティカル カンパニー リミテッド | ピリジン誘導体およびその抗マイコバクテリウムにおける使用 |
| CN105330595B (zh) * | 2014-07-14 | 2019-12-10 | 上海嘉坦医药科技有限公司 | 吡啶衍生物及其作为抗分支杆菌的应用 |
| CN105440051B (zh) * | 2014-09-19 | 2019-07-05 | 重庆医药工业研究院有限责任公司 | 一种抗结核的噻吩吡啶衍生物 |
| CZ2014708A3 (cs) | 2014-10-16 | 2016-04-27 | Zentiva, K.S. | Soli Bedaquilinu |
| CZ201534A3 (cs) | 2015-01-21 | 2016-08-03 | Zentiva, K.S. | Nové možnosti chirální resoluce bedaquilinu |
| CZ201535A3 (cs) | 2015-01-21 | 2016-08-03 | Zentiva, K.S. | Nové možnosti chirální resoluce bedaquilinu |
| CZ201533A3 (cs) | 2015-01-21 | 2016-08-03 | Zentiva, K.S. | Způsob izolace směsi enantiomerů |
| SG11201705944TA (en) | 2015-01-27 | 2017-08-30 | Janssen Pharmaceutica Nv | Dispersible compositions |
| CA2984202A1 (en) * | 2015-04-29 | 2016-11-03 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Anti-phytopathogenic compositions |
| CN106279017A (zh) * | 2015-05-21 | 2017-01-04 | 重庆圣华曦药业股份有限公司 | 贝达喹啉晶型、组合物及其制备方法 |
| CZ2015391A3 (cs) | 2015-06-09 | 2016-12-21 | Zentiva, K.S. | Sůl bedaquilinu s kyselinou citronovou |
| AU2016287477B2 (en) | 2015-07-02 | 2021-10-21 | Janssen Sciences Ireland Uc | Antibacterial compounds |
| CN105061387A (zh) * | 2015-07-17 | 2015-11-18 | 苏州大学 | 二芳基醚类稠环类化合物、制备方法和用途 |
| WO2017015793A1 (zh) * | 2015-07-24 | 2017-02-02 | 浙江海正药业股份有限公司 | 一种分离贝达喹啉非对映异构体a的方法 |
| RU2018111482A (ru) * | 2015-10-20 | 2019-11-21 | Чжэцзян Хисунь Фармасьютикал Ко., Лтд. | Кристаллические формы бедаквилин фумарата и способы их получения |
| CN108473428B (zh) * | 2016-01-13 | 2021-07-23 | 上海嘉坦医药科技有限公司 | 一种吡啶衍生物类化合物的制备方法及其中间体和晶型 |
| EP3423449B1 (en) * | 2016-03-03 | 2021-04-07 | Council of Scientific and Industrial Research | Substituted aurone alkaloids as anti-mycobacterial agents |
| CA3016068C (en) * | 2016-03-07 | 2024-02-27 | The Global Alliance For Tb Drug Development, Inc. | Antibacterial compounds and uses thereof |
| EP3472158A1 (en) | 2016-06-16 | 2019-04-24 | Janssen Sciences Ireland Unlimited Company | Heterocyclic compounds as antibacterials |
| EA201990044A1 (ru) | 2016-06-16 | 2019-05-31 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Гетероциклические соединения в качестве антибактериальных средств |
| EP3589323B1 (en) | 2017-03-01 | 2024-04-03 | Janssen Sciences Ireland Unlimited Company | Combination therapy for the treatment of tuberculosis |
| LT3943070T (lt) | 2017-07-14 | 2024-02-12 | Janssen Pharmaceutica Nv | Ilgo veikimo bedakvilino preparatai |
| CN109384716B (zh) * | 2017-08-11 | 2021-06-29 | 海创药业股份有限公司 | 一种氘代喹啉化合物及其制备和用途 |
| US20220062319A1 (en) | 2019-01-09 | 2022-03-03 | Janssen Pharmaceutica Nv | Combination in the treatment of nontuberculous mycobacterial diseases |
| WO2020161743A1 (en) | 2019-02-08 | 2020-08-13 | Mylan Laboratories Limited | Process for the preparation of bedaquiline fumarate |
| BR112022003799A2 (pt) | 2019-09-13 | 2022-05-24 | Janssen Sciences Ireland Unlimited Co | Compostos antibacterianos |
| WO2021057190A1 (zh) * | 2019-09-29 | 2021-04-01 | 上海阳帆医药科技有限公司 | 喹啉类化合物、其制备方法和用途 |
| MX2022003816A (es) | 2019-09-30 | 2022-05-06 | Janssen Sciences Ireland Unlimited Co | Compuestos antibacterianos. |
| KR20220071199A (ko) | 2019-09-30 | 2022-05-31 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 4-퀴놀리논 항균 화합물 |
| CN110804016B (zh) * | 2019-12-05 | 2022-11-04 | 福建省微生物研究所 | 抗结核分枝杆菌的二芳基喹啉衍生物 |
| PE20221725A1 (es) | 2019-12-27 | 2022-11-04 | Tecnimede Sociedade Tecnico Medicinal Sa | Nuevos compuestos farmaceuticos |
| KR102303635B1 (ko) | 2020-07-01 | 2021-09-17 | 동아에스티 주식회사 | (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법 |
| AU2021303490A1 (en) | 2020-07-09 | 2023-03-09 | Janssen Pharmaceutica Nv | Long-acting formulations |
| CN115776881A (zh) | 2020-07-09 | 2023-03-10 | 詹森药业有限公司 | 长效配制品 |
| EP4178541A1 (en) | 2020-07-09 | 2023-05-17 | JANSSEN Pharmaceutica NV | Long-acting formulations |
| EP4243800A1 (en) | 2020-11-12 | 2023-09-20 | JANSSEN Pharmaceutica NV | Combination of bedaquiline, ethambutol and a macrolide in the treatment of nontuberculous mycobacterial diseases |
| MX2023010947A (es) | 2021-03-16 | 2023-11-29 | Janssen Sciences Ireland Unlimited Co | Compuestos antibacterianos. |
| EP4308238A1 (en) | 2021-03-17 | 2024-01-24 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| US20240182495A1 (en) | 2021-03-17 | 2024-06-06 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2022214520A1 (en) | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2022214519A1 (en) | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2023275744A1 (en) | 2021-06-29 | 2023-01-05 | TECNIMEDE - Sociedade Técnico-medicinal, SA | Heterocyclic compounds for the treatment of tuberculosis |
| TW202325274A (zh) | 2021-10-28 | 2023-07-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 抗菌化合物 |
| WO2023150747A1 (en) | 2022-02-07 | 2023-08-10 | Insmed Incorporated | Dry powder compositions of bedaquiline and salts and methods of use thereof |
| CN114835641B (zh) * | 2022-05-07 | 2024-03-15 | 南京杰运医药科技有限公司 | 一种3-苄基-6-溴-2-甲氧基喹啉的合成方法 |
| WO2023217279A1 (zh) * | 2022-05-13 | 2023-11-16 | 广州嘉越医药科技有限公司 | 一种吡啶衍生物、中间体、制备方法和应用 |
| WO2023232838A1 (en) | 2022-05-31 | 2023-12-07 | Janssen Pharmaceutica Nv | Bedaquiline for use in the treatment of leprosy |
| TW202423427A (zh) | 2022-09-28 | 2024-06-16 | 比利時商健生藥品公司 | 長效配方 |
| WO2024068693A1 (en) | 2022-09-28 | 2024-04-04 | Janssen Pharmaceutica Nv | Long-acting formulations |
| WO2024089170A1 (en) | 2022-10-27 | 2024-05-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2024107555A1 (en) | 2022-11-15 | 2024-05-23 | Eli Lilly And Company | Ahr agonists |
| WO2024223859A1 (en) | 2023-04-26 | 2024-10-31 | Janssen Pharmaceutica Nv | Antibacterial compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001503411A (ja) * | 1996-10-28 | 2001-03-13 | ディパートメント オブ ジ アーミー，ユー．エス．ガバメント | 抗生物質耐性感染症の処置のための化合物、組成物および方法 |
| US6103905A (en) * | 1997-06-19 | 2000-08-15 | Sepracor, Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
| JP2002505689A (ja) * | 1997-06-19 | 2002-02-19 | セプレイコー インコーポレイテッド | キノリン−インドール抗菌剤、それらに関する用途及び組成物 |
| WO1999037365A1 (en) * | 1998-01-23 | 1999-07-29 | Fire Armour Pte Ltd. | Nozzle with axially and perpendicularly directed apertures |
| JP2002501061A (ja) * | 1998-01-26 | 2002-01-15 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 抗菌剤用キノリン誘導体 |
| US6819431B2 (en) * | 2001-07-06 | 2004-11-16 | Zygo Corporation | Polymer retarder |
| EE05394B1 (et) * | 2004-12-24 | 2011-04-15 | Janssen Pharmaceutica N.V. | Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis |
| CA2528849C (en) * | 2005-06-08 | 2014-01-14 | Janssen Pharmaceutica N.V. | Quinoline derivatives as antibacterial agents |
-
2003
- 2003-07-18 JP JP2004523812A patent/JP4484703B2/ja not_active Expired - Lifetime
- 2003-07-18 PT PT03771115T patent/PT1527050E/pt unknown
- 2003-07-18 DE DE60332023T patent/DE60332023D1/de not_active Expired - Lifetime
- 2003-07-18 WO PCT/EP2003/050322 patent/WO2004011436A1/en active IP Right Grant
- 2003-07-18 RS YU20050058A patent/RS52431B/en unknown
- 2003-07-18 NZ NZ538391A patent/NZ538391A/en not_active IP Right Cessation
- 2003-07-18 SI SI200331819T patent/SI1527050T1/sl unknown
- 2003-07-18 DK DK10154018.5T patent/DK2301544T3/da active
- 2003-07-18 CN CN2007101049477A patent/CN101070304B/zh not_active Expired - Lifetime
- 2003-07-18 ME MEP-2008-92A patent/ME00131B/me unknown
- 2003-07-18 AU AU2003262529A patent/AU2003262529B2/en not_active Expired
- 2003-07-18 PL PL375523A patent/PL222801B1/pl unknown
- 2003-07-18 ES ES03771115T patent/ES2343458T3/es not_active Expired - Lifetime
- 2003-07-18 PT PT101540185T patent/PT2301544E/pt unknown
- 2003-07-18 AT AT03771115T patent/ATE463482T1/de active
- 2003-07-18 KR KR1020057000447A patent/KR100733577B1/ko active Protection Beyond IP Right Term
- 2003-07-18 BR BRPI0312927A patent/BRPI0312927B8/pt not_active IP Right Cessation
- 2003-07-18 UA UAA200501778A patent/UA82198C2/uk unknown
- 2003-07-18 EA EA200500257A patent/EA008937B1/ru active Protection Beyond IP Right Term
- 2003-07-18 SI SI200332211T patent/SI2301544T1/sl unknown
- 2003-07-18 DK DK03771115.7T patent/DK1527050T3/da active
- 2003-07-18 EP EP03771115A patent/EP1527050B1/en not_active Expired - Lifetime
- 2003-07-18 AP AP2005003210A patent/AP2421A/xx active
- 2003-07-18 EP EP10154018A patent/EP2301544B1/en not_active Expired - Lifetime
- 2003-07-18 CA CA2493225A patent/CA2493225C/en not_active Expired - Lifetime
- 2003-07-18 ES ES10154018T patent/ES2395237T3/es not_active Expired - Lifetime
- 2003-07-18 CN CNB038177137A patent/CN1325475C/zh not_active Expired - Lifetime
- 2003-07-18 MX MXPA05001052A patent/MXPA05001052A/es active IP Right Grant
- 2003-07-24 AR AR20030102655A patent/AR040673A1/es active IP Right Grant
- 2003-07-24 MY MYPI20032793A patent/MY143564A/en unknown
- 2003-07-24 TW TW092120160A patent/TWI323730B/zh active
-
2004
- 2004-12-08 US US11/007,026 patent/US7498343B2/en active Active
- 2004-12-29 IS IS7620A patent/IS2914B/is unknown
-
2005
- 2005-01-17 HR HRP20050045AA patent/HRP20050045B1/hr not_active IP Right Cessation
- 2005-01-24 IL IL166457A patent/IL166457A/en active IP Right Grant
- 2005-01-24 ZA ZA200500680A patent/ZA200500680B/xx unknown
- 2005-01-27 NO NO20050476A patent/NO329935B1/no not_active IP Right Cessation
-
2006
- 2006-03-17 HK HK06103424A patent/HK1083496A1/xx not_active IP Right Cessation
-
2008
- 2008-04-09 HK HK08103990.6A patent/HK1113795A1/xx not_active IP Right Cessation
-
2009
- 2009-12-10 IL IL202655A patent/IL202655A/en active IP Right Grant
-
2010
- 2010-07-07 CY CY20101100634T patent/CY1111882T1/el unknown
-
2012
- 2012-02-28 HR HRP20120190AA patent/HRP20120190B1/hr not_active IP Right Cessation
- 2012-12-19 CY CY20121101241T patent/CY1113497T1/el unknown
-
2014
- 2014-08-14 NL NL300684C patent/NL300684I2/nl unknown
- 2014-08-14 LU LU92520C patent/LU92520I2/xx unknown
- 2014-08-14 BE BE2014C051C patent/BE2014C051I2/nl unknown
- 2014-08-14 HU HUS1400047C patent/HUS1400047I1/hu unknown
- 2014-08-14 CY CY2014033C patent/CY2014033I1/el unknown
- 2014-08-18 FR FR14C0060C patent/FR14C0060I2/fr active Active
- 2014-08-20 NO NO2014021C patent/NO2014021I1/no not_active IP Right Cessation